‘Significant' progress for Abingdon health as company announces 45 per cent lift in revenues

York-based Abingdon Health has hailed a period of “significant” progress as the company announced that its revenues had grown 45 percent year-on-year.

The company, which develops and manufactures medical diagnostic tests, said that the lift in revenue came after it signed a string of "significant" new contracts during the past year.

Abingdon Health announced total revenues of £4.5m for the six months ending 31 December, up from £3.1m in the same period a year prior.

Speaking on the results, Chris Hand, executive chairman of Abingdon Health, said: "I am pleased to report substantial revenue growth in the first six months of the financial year, and the outlook for the rest of FY26 and beyond remains positive.”

In a statement to the London Stock Exchange, the boss of Abingdon Health has hailed a period of “significant” progress. ( Photo by Jeff Moore/PA Wire)placeholder image
In a statement to the London Stock Exchange, the boss of Abingdon Health has hailed a period of “significant” progress. ( Photo by Jeff Moore/PA Wire)

Abingdon said its board had chosen to maintain the firm’s revenue guidance for the full-year, in line with market expectations of £12.6m – including £0.4m grant funded revenue.

The firm also announced cash and cash equivalents at 31 December 2025 of £3.6m, up from £1.9m at the end of June.

This followed the company's recent fundraise in October 2025 which raised £3.2m net of expenses, as the firm looked to accelerate its expansion into the US.

Abingdon said that the speed of its US expansion, as well as its new customer wins, were set to drive its core earnings in the full year.

The firm is currently increasing its lateral flow development and manufacturing footprint in Madison, Wisconsin. It said this had been done to keep up with customer demand.

A statement from Abingdon issued to the London Stock Exchange added: “The board anticipates H2 FY26 to be profitable and operating cash flow positive whilst the outturn for the year will depend largely on anticipated continued commercial progress throughout H2.”

In November, Abingdon announced a new multi-million dollar contract with an unnamed American firm.

The firm said it had signed a Master Service Agreement with a US-based company for the development and scale up to manufacture of a semi-quantitative, multiplex lateral flow test system with an expected value of around $2m (£1.5m).

The announcement follows Abingdon stating in September that it had five new development projects under way in the US.

Abingdon said at the time that projects under way include the development of a lateral flow veterinary product for use initially in dog samples, and feasibility work with a leading US university to evaluate novel nanoparticles for use in a lateral flow format.

The firm also said it was working on developing a lateral flow test for infectious disease, initially in cows, and developing a test for an infectious agent in animals and humans, with a spin-out of a leading US university.

Abingdon said it expects to report its first-half results in March 2026.

Related topics:
News you can trust since 1754
Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice